What Was Approved?
On June 26, 2026, the U.S. Food and Drug Administration approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease, or TED.
The FDA-approved indication applies regardless of the activity or duration of the disease.
FDA also lists Lumvoa among its 2026 novel drug approvals.
What Is Thyroid Eye Disease?
Thyroid eye disease is an autoimmune condition that affects tissues around the eyes.
It is often associated with thyroid disorders such as Graves’ disease, although the eye condition and thyroid hormone levels do not always follow the same course.
Possible symptoms can include:
- Eye bulging
- Swelling around the eyes
- Redness
- Eye discomfort
- Double vision
- Difficulty fully closing the eyelids
The severity of symptoms varies from person to person.
What Is Lumvoa?
Lumvoa contains veligrotug-vvze, a monoclonal antibody that inhibits the insulin-like growth factor-1 receptor, or IGF-1R.
IGF-1R signaling is involved in the biological processes that contribute to inflammation and tissue changes in thyroid eye disease.
By blocking this receptor, Lumvoa is intended to reduce disease-related changes in tissues around the eye.
How Is Lumvoa Given?
According to the FDA-approved prescribing information, the recommended dose is:
10 mg/kg by intravenous infusion every three weeks for a total of five infusions.
Each infusion is administered over approximately 30 to 45 minutes.
Treatment should be given under the supervision of a healthcare professional.
What Did the Clinical Studies Show?
FDA reviewed two pivotal clinical studies evaluating Lumvoa in patients with thyroid eye disease.
According to FDA review documents:
- About 70% of patients with active TED treated with veligrotug achieved a reduction in proptosis of at least 2 millimeters.
- About 57% of patients with chronic TED achieved that level of improvement.
Proptosis refers to forward bulging of the eye.
These results describe outcomes observed in the clinical trials and do not guarantee that every patient will experience the same response.
What Are the Most Common Side Effects?
According to the FDA-approved prescribing information, common adverse reactions occurring in at least 5% of patients included:
- Muscle spasms
- Headache
- Hearing impairment
- High blood sugar
- Fatigue
- Diarrhea
- Ear discomfort
- Infusion-related reactions
- Nausea
- Nasopharyngitis
- Increased creatine phosphokinase
- Dry skin
- High blood pressure
Other adverse effects can also occur.
What Are the Important Safety Warnings?
The FDA-approved labeling includes several important warnings and precautions.
Infusion Reactions
Infusion-related reactions can occur during treatment.
If a reaction occurs, the infusion may need to be slowed or temporarily stopped, and appropriate medical treatment may be required.
Inflammatory Bowel Disease
Lumvoa may worsen pre-existing inflammatory bowel disease.
Patients with inflammatory bowel disease should be monitored for worsening symptoms during treatment.
Hyperglycemia
Lumvoa can cause hyperglycemia, or elevated blood glucose.
This may be especially important for patients who already have diabetes or difficulty controlling their blood sugar.
Blood glucose monitoring and adjustments to diabetes treatment may be necessary.
Hearing Impairment
Hearing problems can occur with Lumvoa.
The prescribing information warns that hearing impairment, including hearing loss, may be severe and may be permanent in some cases.
Patients should promptly report changes in hearing, ringing in the ears, ear fullness, or other new hearing symptoms.
Does Lumvoa Have Any Contraindications?
The FDA-approved prescribing information lists no formal contraindications.
However, that does not mean the medicine is appropriate for everyone.
A healthcare professional should still review the patient’s medical history, current medications, diabetes status, gastrointestinal history, hearing problems, and other relevant conditions before treatment.
Are There Pregnancy Considerations?
Yes.
Because IGF-1R signaling plays an important role in fetal development, the prescribing information includes precautions related to pregnancy.
Patients who could become pregnant should use appropriate contraception before treatment, during treatment, and for 6 months after the final Lumvoa dose.
Pregnancy-related questions should be discussed with the treating healthcare professional.
Why Is This Approval Important?
Thyroid eye disease can affect vision, eye movement, appearance, and quality of life.
Lumvoa provides another targeted treatment option for TED and is specifically approved without limiting use based on whether the disease is active or how long the patient has had it.
Its five-infusion treatment schedule also distinguishes it from some other treatment approaches.
Bottom Line
Lumvoa (veligrotug-vvze) is a newly FDA-approved intravenous treatment for thyroid eye disease regardless of disease activity or duration.
It is given as five infusions, spaced three weeks apart, and works by inhibiting the IGF-1 receptor.
Important risks include infusion reactions, worsening inflammatory bowel disease, hyperglycemia, and hearing impairment, including potentially permanent hearing loss.
Patients should be evaluated and monitored by a healthcare professional experienced in managing thyroid eye disease.
Sources
- U.S. Food and Drug Administration (FDA) — Novel Drug Approvals for 2026.
- U.S. Food and Drug Administration (FDA) — Lumvoa Approval Package, June 26, 2026.
- U.S. Food and Drug Administration (FDA) — Lumvoa (veligrotug-vvze) Prescribing Information, revised June 2026.
- DailyMed — Lumvoa (veligrotug-vvze) Official Drug Label.